BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 26835380)

  • 1. Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.
    Bassiri H; Benavides A; Haber M; Gilmour SK; Norris MD; Hogarty MD
    Transl Pediatr; 2015 Jul; 4(3):226-38. PubMed ID: 26835380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
    Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA; Ziegler DS; Webber H; Hayes CS; Pawel B; Marshall GM; Zhao H; Gilmour SK; Norris MD; Hogarty MD
    Clin Cancer Res; 2016 Sep; 22(17):4391-404. PubMed ID: 27012811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
    Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
    Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
    Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
    Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
    Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
    PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
    Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
    Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma.
    Gamble LD; Purgato S; Murray J; Xiao L; Yu DMT; Hanssen KM; Giorgi FM; Carter DR; Gifford AJ; Valli E; Milazzo G; Kamili A; Mayoh C; Liu B; Eden G; Sarraf S; Allan S; Di Giacomo S; Flemming CL; Russell AJ; Cheung BB; Oberthuer A; London WB; Fischer M; Trahair TN; Fletcher JI; Marshall GM; Ziegler DS; Hogarty MD; Burns MR; Perini G; Norris MD; Haber M
    Sci Transl Med; 2019 Jan; 11(477):. PubMed ID: 30700572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyamine synthesis as a target of
    Bachmann AS; Geerts D
    J Biol Chem; 2018 Nov; 293(48):18757-18769. PubMed ID: 30404920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
    Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
    Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases.
    LoGiudice N; Le L; Abuan I; Leizorek Y; Roberts SC
    Med Sci (Basel); 2018 Feb; 6(1):. PubMed ID: 29419804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma.
    Gamble LD; Hogarty MD; Liu X; Ziegler DS; Marshall G; Norris MD; Haber M
    Front Oncol; 2012; 2():162. PubMed ID: 23181218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.
    Koomoa DL; Yco LP; Borsics T; Wallick CJ; Bachmann AS
    Cancer Res; 2008 Dec; 68(23):9825-31. PubMed ID: 19047162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
    Meyskens FL; Gerner EW
    Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.
    Koomoa DL; Geerts D; Lange I; Koster J; Pegg AE; Feith DJ; Bachmann AS
    Int J Oncol; 2013 Apr; 42(4):1219-28. PubMed ID: 23440295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.
    Evageliou NF; Hogarty MD
    Clin Cancer Res; 2009 Oct; 15(19):5956-61. PubMed ID: 19789308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
    Schultz CR; Swanson MA; Dowling TC; Bachmann AS
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):607-617. PubMed ID: 34129075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further studies on difluoromethylornithine in African trypanosomes.
    McCann PP; Bacchi CJ; Clarkson AB; Seed JR; Nathan HC; Amole BO; Hutner SH; Sjoerdsma A
    Med Biol; 1981 Dec; 59(5-6):434-40. PubMed ID: 6175860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma.
    Lozier AM; Rich ME; Grawe AP; Peck AS; Zhao P; Chang AT; Bond JP; Sholler GS
    Oncotarget; 2015 Jan; 6(1):196-206. PubMed ID: 25415050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual and combined effects of alpha-difluoromethylornithine and ovariectomy on the growth and polyamine milieu of experimental breast cancer in rats.
    Manni A; Badger B; Glikman P; Bartholomew M; Santner S; Demers L
    Cancer Res; 1989 Jul; 49(13):3529-34. PubMed ID: 2499419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO).
    Kadmon D
    J Cell Biochem Suppl; 1992; 16H():122-7. PubMed ID: 1289667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.